179 related articles for article (PubMed ID: 16970257)
1. Darbepoetin use for the treatment of anemia in hemodialysis patients in Saudi Arabia.
Shaheen FA; Akeel N; Alfi A; Harbi A; Tarif N; Souqiyyeh MZ
Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):365-72. PubMed ID: 16970257
[TBL] [Abstract][Full Text] [Related]
2. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of darbepoetin alpha in hemodialysis patients resistant to human recombinant erythropoietin (rHuEpo).
Hejaili F
Saudi J Kidney Dis Transpl; 2009 Jul; 20(4):590-5. PubMed ID: 19587498
[TBL] [Abstract][Full Text] [Related]
4. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
[TBL] [Abstract][Full Text] [Related]
5. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
6. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
Mahajan S; Boulton H; Gokal R
J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
[TBL] [Abstract][Full Text] [Related]
7. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
8. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.
Agrawal V; Mukherjee S; Kosuri R; Dumler F
Am J Ther; 2010; 17(5):469-75. PubMed ID: 19770634
[TBL] [Abstract][Full Text] [Related]
9. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
Jadoul M; Vanrenterghem Y; Foret M; Walker R; Gray SJ
Nephrol Dial Transplant; 2004 Apr; 19(4):898-903. PubMed ID: 15031347
[TBL] [Abstract][Full Text] [Related]
10. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
[TBL] [Abstract][Full Text] [Related]
12. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
[TBL] [Abstract][Full Text] [Related]
13. [Resistance index to epoetin alpha and to darbepoetin-alpha in chronic hemodialysis patients: a cohort study].
Pérez-García R; Rodríguez Benítez P; Jofre R; López-Gómez JM; Villaverde MT; Blanco A; Blanco S; Sánchez M
Nefrologia; 2007; 27(3):340-9. PubMed ID: 17725454
[TBL] [Abstract][Full Text] [Related]
14. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
[TBL] [Abstract][Full Text] [Related]
15. Phase III clinical trials with darbepoetin: implications for clinicians.
Glaspy J
Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
[TBL] [Abstract][Full Text] [Related]
17. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
18. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration.
Toto RD; Pichette V; Navarro J; Brenner R; Carroll W; Liu W; Roger S
Am J Nephrol; 2004; 24(4):453-60. PubMed ID: 15331889
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
Fang YW; Chang CH
Perit Dial Int; 2009; 29(2):199-203. PubMed ID: 19293358
[TBL] [Abstract][Full Text] [Related]
20. [Italian study on the treatment of anaemia in chronic dialysis patients switched over to less frequent doses of darbepoetin from human recombinant erythropoietin (rHuEPO)].
Del Vecchio L; Villa G; Carraro G; Morosetti M; Pedrini L; Adorati Menegato M; Amato M; Mauro MM; Borgatti P; Malberti F; Marai P; Locatelli F;
G Ital Nefrol; 2004; 21(3):259-66. PubMed ID: 15285005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
